



BIO International Convention 2025

VICTORIAN EXHIBITOR DIRECTORY

MELBOURNE • VICTORIA • AUSTRALIA

16 - 19 June 2025





Australia's Health and Life Sciences Powerhouse

Melbourne, Victoria, Australia, is one of the world's leading Health and Life Sciences clusters.

As an exceptionally collaborative, globally connected life sciences ecosystem, the city is a highly sought-after destination by global companies and is ranked in the top 5 of Life Sciences Hubs in Asia Pacific.

Melbourne is one of the few cities in the world to have two universities in the global top 35 for Life Sciences and Medicine, and Monash University is ranked #2 in the world for pharmacy and pharmacology. This academic reputation produces over 24,000 graduates in health and sciences annually.

Our city has 22 internationally recognised research institutes, and 12 teaching hospitals that provide outstanding capabilities in neuroscience, oncology, neurology, genomics, cardiovascular health, paediatrics, regenerative medicine, and immunology and infectious diseases. Centred around 3 research precincts; Melbourne Biomedical (Parkville), Clayton, and La Trobe, Melbourne's Health and Life Sciences ecosystem brings together world-leading research organisations, top-tier universities and hospitals and the most exciting biotech and medtech startups to develop and manufacture revolutionary preventions, diagnostics, and treatments for disease.

We offer a low-risk, high-quality and competitive business environment with a rich legacy of commercial success. This is facilitated by a highly skilled workforce drawn from around the globe, accessible R&D infrastructure, world-class IP protections, robust and efficient regulatory frameworks recognised by key global markets, an attractive R&D tax incentive, and advanced manufacturing expertise. Home to Australia's largest curfew-free airport and container port offering world-class freight and logistics infrastructure, connecting companies to the Asia-Pacific, and the rest of the world.

Victoria is a preferred destination for clinical trials for the world's leading pharmaceutical companies, with more than 90% of phase 1 clinical trials conducted in Victoria sponsored by international firms. It is the Australian leader for early-stage trials, and is home to one-third of Australia's dedicated phase I facility beds, and one-third of all clinical trials conducted in Australia. Victoria's reputation for high-quality, cost and time efficient trials is underpinned by a world-leading healthcare system and highly-skilled workforce including recognised Key Opinion Leaders, robust and simplified regulatory framework and approval process which does not require US FDA Investigational New Drug (IND) application approval, diverse participant population that represent key global markets, and an attractive R&D tax incentive.



We can help you do business with Melbourne, Victoria, Australia.

The State Government of Victoria, Australia - through its trade facilitation branch, Global Victoria and investment attraction branch, Invest Victoria - is responsible for connecting Victorian businesses to global market opportunities and attracting new investment into the state.

Through our global network of 23 trade and investment offices, we work with international partners to support the development and commercialisation of breakthrough products and treatments.

The Victorian Government recognises Health and Life Sciences as a priority sector and has a long track record of providing supporting across the breadth of the ecosystem.

Our team can help you with market entry or expansion into Melbourne, Australia. We also provide free, confidential services to connect you with key partners and suppliers.

Contact us - American Office

Carolyn McCaffrey

Director Investment and Trade,
Health & Life Sciences, Americas

Email: carolin.mccaffrey@global.vic.gov.au

Phone: +1 415 539 8402

Sofia O'Hara

Trade & Investment Manager,
Health & Life Sciences, Americas

Email: sofia.ohara@global.vic.gov.au

Phone: +1 415 298 2455

Contact us - Australian Office

Libby Kruse

Trade Manager,
Health & Life Sciences

Email: libby.x.kruse@ecodev.vic.gov.au

Phone: +61 407 962 213



BIO International Convention 2025 Victorian Exhibitor Directory



360biolabs

360biolabs is Australia's most comprehensive bioanalytical laboratory providing a single laboratory for all of your clinical trial requirements.

We support pharmacokinetic (PK) analysis, a diverse range of pharmacodynamic (PD) endpoints and central lab services in a quality assured environment. Our team of highly experienced scientific and QA professionals ensures high quality science, data integrity and regulatory compliance through all phases of clinical development.

www.360biolabs.com



Ms Angela Luttick
EVP, Commercial

Email: angela.luttick@360biolabs.com

Phone: +61 400 641 333



BIO International Convention 2025 Victorian Exhibitor Directory



Accelagen Pty Ltd

Accelagen is a leading, locally positioned and globally adept Contract Research Organisation (CRO) headquartered in Australia working with innovative clients across the globe to make a tangible impact on the future of human health and wellness.

With over a decade of delivered success, our experience is widely varied across the health, wellness and disease spectrum. We offer end-to-end services across Strategic Consultation, Human Clinical Trials, Regulatory Affairs, and Biometrics.

www.accelagen.com.au



Mr Mathew Palmer
Chief Growth & Commercial Officer
Email: mathew.palmer@accelagen.com.au
Phone: +61 431 479 709

Mr Trent Wadsford
Senior Director, Business Development
Email: trent.wadsford@accelagen.com.au



BIO International Convention 2025 Victorian Exhibitor Directory



Acclime Corporate Services Australia Pty Ltd

The Acclime Group operates in 14 jurisdictions across Australasia, Asia, and the USA, providing specialized Market Entry Advisory and Corporate Services to life science and healthcare companies. With decades of experience across various therapeutic areas, our team supports businesses from preclinical evaluation to post-marketing commercialization.

Our Market Entry Advisory Services include:

- Opportunity assessment and strategic roadmaps.
- Clinical trial support, including guidance on Australia's generous Tax Incentives.
- Company incorporation, resident directorships, accounting, and tax services.
- Regulatory guidance and product registration across Asia.

Acclime Australia helps life science companies establish a presence, ensuring seamless compliance, tax optimization, and business operations. We have successfully advised on market entry strategies, partnerships, and regulatory requirements throughout the region.

Meet us at BIO International Convention 2025 in Boston to explore how Acclime can support your expansion into Australia and Asia.

www.acclime.com



Mr Luis Silva
Business Development Manager, Australia
Email: l.silva@acclime.com
Phone: +61 432 972 770



Mr Gaurav Kirti
Head of Strategic Partnerships N America
Email: g.kirti@acclime.com
Phone: +91 124 494 2050



BIO International Convention 2025 Victorian Exhibitor Directory



Aeterna Health Pty Ltd

Aeterna Health Pty Ltd is a biotech company focused on regenerative medicine, clinical research, and autologous stem cell therapies focused on solid tumors, autoimmune diseases, and anti-aging solutions. With expertise in stem cell (svCell) and immune cell (iCell) applications, we develop innovative therapies that address complex medical challenges.

At BIO International Convention 2025, we aim to explore the U.S. biotech market, connect with potential investors and funding sources, identify licensing opportunities in biotech, and establish strategic partnerships for clinical trials. Expanding into the U.S. market will help accelerate research, drive clinical applications, and bring regenerative therapies to a broader audience.

www.aeternahealth.com.au



Mr Riddick Jie
Director

Email: riddick@aeternahealth.com.au



BIO International Convention 2025 Victorian Exhibitor Directory



Akaal Pharma Pty Ltd

Akaal Pharma is a private, clinical-stage, Australian biotechnology company focused on advancing our internally discovered topical and oral programs. Akaal Pharma is developing new therapies, selective S1P1 agonists (a class of GPCRs) for the treatment of diseases with significant large unmet medical need.

Akaal Pharma has discovered a ground-breaking technology AK-119 with the potential to revolutionize treatments for autoimmune, inflammatory, and neuronal diseases.

Akaal Pharma has completed multiple human Phase I clinical trials targeting inflammatory disorders (2 topical clinical Phase 1 studies and 1 oral clinical Phase I study) and is currently completing a human Phase II clinical trial study with 139 patients (targeting atopic dermatitis and pruritis).

Akaal Pharma is seeking strategic partners/investors to further develop our lead asset, access to our selective libraries of small molecule S1P1 agonists for new therapeutic indications.

www.akaalpharma.com



Dr Tony Rajic
CEO

Email: tony.rajic@akaalpharma.com

Phone: +61 418 804 677



BIO International Convention 2025 Victorian Exhibitor Directory



Akesa

At Akesa, we embrace the innovative spirit that drives new drug development.

For over 11 years, we've been recognized as an Asia Pacific regional expert with global reach. Our vast market knowledge, consultative approach, and strong supplier relationships set us apart. We understand the unique challenges sponsors face when sourcing registered pharmaceuticals and use our global network to source products and product documentation directly from manufacturers and validated suppliers.

Akesa's clinical trial supply services include:

- Comparator
- Combination therapies
- Concomitant
- Samples for analysis
- Ancillaries

Akesa's trial services offer a complete, end-to-end solution for clinical trial supply needs, covering project management, forecasting, planning, product sourcing, labelling, storage, and distribution - directly to site or patient. Akesa's on-demand clinical trial site sourcing solution is designed to simplify and streamline the supply of clinical trial medicines for sponsors, pharmacies, and clinical trial sites. With a steadfast commitment to excellence, we help bring your drug to market.

www.akesagroup.com



Ms Karen Montgomery-Douglas
Commercial Development Manager

Email: karen.m@akesagroup.com

Phone: +61 400 322 339



BIO International Convention 2025 Victorian Exhibitor Directory



Alithia Life Sciences Pty Ltd

Alithia Life Sciences is an Australian owned boutique, full-service capability Contract Research Organization (CRO) launched to support and assist pharmaceutical, biotechnology, device companies, and institutional research groups undertaking their project in the Australian region and beyond.

We have an average of 20+ years of operational expertise and industry experience in various therapeutic areas including, First In Human studies (FIH), devices, endocrinology, oncology, neurology, gastroenterology, rare and pediatric diseases, and vaccines.

Our breadth of expertise in the academic, commercial, and biotechnology settings can support your project from Phase I through to Phase III.

Our local and global experience includes developing products successfully through to FDA approval, executive management, and previous establishment of a successful Contract Research Organization (CRO).

www.alithialifesciences.com



A/Prof Tina Soulis
Founder and Director

Email: tina.soulis@alithialifesciences.com

Phone: +61 429 300 705



BIO International Convention 2025 Victorian Exhibitor Directory



Arovella Therapeutics

Arovella is developing a unique CAR-iNKT cell therapy platform to generate allogeneic (off-the-shelf) cell therapy products to tackle blood cancers and solid tumors.

It is one of a handful of companies developing CAR-iNKT cells globally, and it is focusing on iNKT cells due to the unique properties that they possess. These include the ability to be used off-the-shelf, without the risk of causing graft versus host disease, their ability to naturally and rapidly eliminate cancer cells, and their ability to shape the tumor microenvironment, and cross prime other immune cells.

Arovella's lead product is being developed to target lymphoma and leukemia and it is also developing products to target solid tumors, including gastric cancer, and potentially pancreatic cancer.

Arovella's mission is to be a world leading company, helping cancer patients live longer and healthier lives.

www.arovella.com



Dr Michael Baker
CEO and MD

Email: mbaker@arovella.com

Phone: +61 403 468 187



BIO International Convention 2025 Victorian Exhibitor Directory



Arrotex Pharmaceuticals

Arrotex Pharmaceuticals offers the most extensive range of molecules and prescription products, across many therapeutic areas, in Australia. We offer a total market solution encompassing prescription generics, branded partnerships, biologics/biosimilars, professional services, generic OTC, consumer brands, and retail services.

Arrotex is the ideal partner of choice to bring your products to market in Australia.

www.dbghealth.com.au



Mr Scott Voller
General Manager Business Development

Mr George Katsanos
BD Commercial Innovations Manager



BIO International Convention 2025 Victorian Exhibitor Directory



Attentive Science Australia

Attentive Science is an FDA inspected, AAALAC accredited premier global leader, excelling in GLP and nonGLP in-vivo pharmacokinetics, toxicology, and safety pharmacology services. We serve the biotech, pharmaceutical, agrochemical and animal health industries, ensuring that data generated are accurate, complete, and verifiable paired with a personalized client service.

Our team, with over two centuries of combined scientific experience, possesses extensive expertise in various test substances, test systems, routes of administration, and the overall conduct of preclinical (non-clinical) studies. This rich background ensures Attentive Science remains at the forefront of innovation, leveraging cutting-edge technologies and industry-leading methodologies to empower critical decision-making milestones.

www.attentivescience.com



Dr Alfred Botchway

CEO

Email: alf@attentivescience.com



BIO International Convention 2025 Victorian Exhibitor Directory



Avion Full Service CRO & Research Imaging Specialists

Avion is a leading full-service CRO & imaging specialist partner for clinical trials and medical research delivering end-to-end clinical trial solutions. With expertise in Oncology, Nuclear Medicine and Theranostics, Research Imaging, Dermatology, Nutrition and more, we partner with pharmaceutical, biotech, and medical device companies to ensure successful completion of trials in all stages of development.

Headquartered in Melbourne, Avion fully understand the highly favorable research environment that Australia provides and also work globally with far reaching capabilities and experience. Our team's commitment to quality and innovation ensures seamless execution of complex clinical studies, providing tailored solutions to meet the unique needs of each trial, optimizing outcomes and accelerating the development of life-changing treatments.

We specialize in early phase clinical trials and understand how critical and complex early-stage clinical development is. By leveraging decades of research experience and an unparalleled working relationship with industry and clinicians, we provide a solution that is driven by the latest knowledge to deliver on company needs. We also possess niche expertise in the clinical development of radiopharmaceuticals to ensure successful completion of theranostic projects.

www.avionmedical.com.au



Dr Jerome Barley
Commercial Director
Email: jerome@avionmedical.com.au
Phone: +61 451 049 422



Dr Sam Vohra
Founder & CEO
Email: sam@avionmedical.com.au
Phone: +61 450 556 969



BIO International Convention 2025 Victorian Exhibitor Directory



BaseBio consulting

BaseBio is a consultancy focused on delivery of clinical operations for clinical trials in Australia. Our consultants collaborate with Biotech, Medtech, and pharmaceutical companies in set up to close out of clinical trials.

We provide comprehensive due diligence and budget support services to streamline the vendor selection process for our clients, helping them make informed decisions to choose their vendors to support studies in Australia, while supporting the requirements for the R&D Tax incentive. Our goal is to simplify complex processes, allowing our clients to focus on advancing their research and achieving successful outcomes in their clinical trials.

www.basebio.com.au



Ms Rachelle Kirk-Burnnand
Managing Director
Email: rachelle@basebio.com.au



BIO International Convention 2025 Victorian Exhibitor Directory



BioCurate Pty Ltd

BioCurate's mission is to grow the Victorian and Australian biotech sector by translating medical research outputs into high quality preclinical candidates for the bio-pharmaceutical industry.

A bold, collaborative venture, BioCurate was jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government. BioCurate is dedicated to identifying promising biomedical research discoveries and managing their translation into high quality pre-clinical candidates.

BioCurate's team of experts bring hands-on industry experience and a global track-record, providing a robust bridge between academia and industry within the biotechnology sector to accelerate the development of new therapies. We can help you change the future.

www.biocurate.com



Ms Metani Rooms
COO

Email: m.rooms@biocurate.com

Phone: +61 429 463 872



Dr Katherine Nielsen
CEO

Email: k.nielsen@biocurate.com

Phone: +61 235 675 589



BIO International Convention 2025 Victorian Exhibitor Directory



Burnet Institute

Burnet Institute is an Australian-based not-for-profit, independent medical research and public health institute and international non-government organisation that is working towards a more equitable world through better health.

Burnet undertakes a range of programs across the Indo-Pacific region and in Africa that focus on global health issues in the areas of Disease Elimination, Health Security, Pandemic Preparedness, and Maternal, Child and Adolescent Health.

In addition to developing several technologies with intellectual property protections in the fields of infectious disease, diagnostics, and cancer, we have certified and dedicated facilities for developing point-of-care diagnostics and vaccines that adhere to ISO standards. We also have a large public health team which are adept at running clinical trials, participating in co-design studies, performing health economics analysis and working with clinical teams to transform policy and practice. Collectively these capabilities form the basis of co-development, licensing, and/or fee-for-service opportunities with external organisations.

www.burnet.edu.au



Dr Carli Roulston
Senior Manager, Business Development
Email: carli.roulston@burnet.edu.au



Miss Jennifer Barnes
Director, Commercialization Translation
Email: jennifer.barnes@burnet.edu.au



BIO International Convention 2025 Victorian Exhibitor Directory



Canary Regulatory Affairs

Canary Regulatory Affairs is a boutique consultancy specialized in the biotech, pharmaceuticals, and medical devices sectors with an international focus.

We offer bespoke scientific and strategic advice tailored to our clients' unique needs. Our goal is to guide our clients to obtain regulatory approval from agencies such as the EMA, FDA, MHRA and TGA. Our expertise spans quality, manufacturing as well as non-clinical and clinical development, making us particularly adept at supporting companies in the early stages of their development.

We excel at negotiating data requirements with regulators, both before submission and during the review process, ensuring a smooth pathway to approval.

We collaborate closely and forge enduring relationships with our clients and partners at any stage of the development process. We are passionate about our work, and we take pride in celebrating our clients' achievements as if they were our own.

www.canaryregulatory.com



Ms Nicoletta Muner

Founder and Managing Director

Email: nicoletta@canaryregulatory.com

Phone: +61 412 765 896



BIO International Convention 2025 Victorian Exhibitor Directory



**Cancer Trials
Australia**

Cancer Trials Australia

Cancer Trials Australia (CTA) is a highly effective member based clinical trial network and site service organization, which has provided clinical trial administrative support to its members for over 20 years. Since its inception in 2003, CTA has administered the start-up and management of over 2,400 oncology clinical trials, sponsored by over 350 different organizations that have recruited in excess of 14,000 Australian patients.

CTA administers oncology clinical trials that range from first-time-in-human trials to large scale Phase III trials. With 37 members throughout Australia and New Zealand, collaboration across these members provides a significant opportunity for sponsors to conduct multi-site clinical trials, accruing significant patient numbers quickly, despite our relatively small population. Australia is recognized as a hub for early phase clinical trials and many international biotech and pharmaceutical companies continue to launch early phase trials in Australia, taking advantage of the quality of data produced, as well as associated speed and cost benefits. CTA has an established Phase I Group and administers >60% of all Phase I oncology trials within Australia. This unique clinical group includes key opinion leaders who can review pre-clinical data and quickly offer impartial recommendations regarding study design, strategy, and relevant submissions.

www.cancertrialsaustralia.com



Dr Kurt Lackovic

CEO

Email: kurt.lackovic@ctaust.org

Phone: +61 439 352 455



BIO International Convention 2025 Victorian Exhibitor Directory



Cannenta

Cannenta is developing a range of effective and affordable proangiogenic wound care products, utilizing patented 2DDR technology to address the global market for first line treatment of chronic wounds.

www.cannenta.com



Mr Iain Ralph

MD

Email: iain.ralph@cannenta.com

Phone: +61 409 141 769



BIO International Convention 2025 Victorian Exhibitor Directory



Cartherics Pty Ltd

Cartherics is developing the next generation of cell-based products. It uses the full power of its cell therapy platform to develop novel therapies to treat cancer and offer new approaches to the treatment of other intractable diseases such as endometriosis and neuroinflammatory conditions. It is seeking research, development and strategic partners to help exploit the power of its technology platform.

www.cartherics.com



Dr Ian Nisbet

Chief Operating Officer

Email: ian.nisbet@cartherics.com

Phone: +61 431 709 121



BIO International Convention 2025 Victorian Exhibitor Directory



CBE Pure Solutions

CBE Pure Solutions (CBEPS) is a specialized Australian contract manufacturing and testing organisation (CMO) that focuses on the development, translation, and commercialization of Life Science products.

CBEPS is dedicated to supporting the growth of the Medical, Technology, and pharmaceutical sector in Australia through the onshoring of innovation.

CBEPS expertise lies in providing fill and finish services and microbiological testing services. CBEPS operate a state-of-the-art facility in Melbourne's SE Biotech precinct, designed for Good Manufacturing Practice (cGMP) and compliance to local and international standards. The company specializes in aseptic fill and finish services for liquid medicinal products and medical devices, offering comprehensive monitoring and testing services, including environmental monitoring and sterility testing. The services cover a wide range of products including placebos, diagnostics, vaccines, and therapies across biologics, pharmaceuticals, APIs, medical foods, animal health, and emerging technologies.

www.cbepuresolutions.com



Mrs Justine Mann
CEO

Email: justine.mann@cbepuresolutions.com

Phone: +61 423 781 732



Dr Wayne Adcock
Business Development Manager

Email: Wayne.Adcock@cbepuresolutions.com

Phone: +61 418 586 183



BIO International Convention 2025 Victorian Exhibitor Directory



Commercializing
Living Therapies

CCRM Australia Ltd

CCRM Australia accelerates the commercialization of regenerative medicine therapies and related technologies. We do this by providing specialist expertise, funding opportunities and connections between industry, clinicians, researchers, and other key stakeholders.

CCRM Australia offers a number of market consulting services to understand and validate the potential of their technology, such as identifying problems and unmet needs, determining ideal customer profile and market size, understanding the competitive landscape and creating a Target Product Profile. Our services extend to address any challenges that lie along the route to market from preclinical, clinical trials, process development, and cGMP manufacturing.

www.ccrmaustralia.com.au



Mr Silvio Tiziani
CEO

Email: silvio.tiziani@ccrmaustralia.com.au

Phone: +61 418 536 209



BIO International Convention 2025 Victorian Exhibitor Directory



Cell Therapies Pty Ltd

Cell Therapies Pty Ltd (CTPL) is Australia's leading GMP contract manufacturer for cell and gene therapies, with over 20 years of experience spanning first-in-human to commercial supply.

Co-located with the Peter MacCallum Cancer Centre in Melbourne, our facility features 13 GMP cleanrooms, integrated QC labs, cryostorage, and regulatory credentials across TGA, FDA, PMDA, and EMA. CTPL is the only Australian CDMO with Japanese MHLW accreditation and capacity for commercial-scale manufacturing of autologous and allogeneic therapies, including CAR-T and iPSC-derived products.

We offer a hybrid service model — combining process development, GMP manufacturing, analytical support, and regional regulatory guidance — tailored to your CGT program's lifecycle. Companies conducting clinical trials in Australia may benefit from a 43.5% R&D tax incentive, offering significant savings and expedited timelines.

Shift to CTPL for all your APAC CGT needs — meet us at BIO 2025 to explore strategic partnerships and regional expansion opportunities.

www.celltherapies.com



Dr Shrinidh Joshi
Director of Business Development
Email: shrinidhjoshi@celltherapies.com.au
Phone: +1 437 987 3760



BIO International Convention 2025 Victorian Exhibitor Directory



Celleo

Celleo - Intelligent Production Systems for Cell Therapy.

Our lead product family - Larkem - sets a powerful benchmark for CGT Formulate + Fill.

Closed processing in Grade C/D.

Flexible across multi-format vials and bags.

Fast fills in minutes.

Gentle on cells.

www.celleo.com



Mr David Kneen

CEO

Email: david.kneen@celleo.com



Dr Nicholas Boyd

Head of Biology

Email: nicholas.boyd@celleo.com



BIO International Convention 2025 Victorian Exhibitor Directory



Central Pharmacy Logistics Pty Ltd

CPL is a supply chain company with the core of its service "Direct to Patient" allowing for Investigational Product, in a clinical trial, to be delivered and administered in the patient's home.

CPL are the first in Australia to be licensed by the Pharmacy Authority to deliver clinical trial therapies direct to a patient's home regardless of geographical location.

www.cplaustralia.com



Ms Rebecca Pearce

Director of Commercial Development

Email: Rebecca.pearce@cplaustralia.com

Phone: +61 452 156 100



BIO International Convention 2025 Victorian Exhibitor Directory



Certa Therapeutics

A clinical-stage biotechnology company developing innovative precision therapies for the treatment of fibrotic diseases, Certa is addressing an area of significant unmet need that ultimately causes 35% of all deaths globally and represents a \$15bn market.

Certa's pipeline targets a 'master switch' of fibrosis, GPR68, with a series of inhibitors tailored for different fibrotic indications. Its lead program, asengeprast (FT011), is being developed as a novel, first-in-class oral therapy for the treatment of systemic sclerosis (scleroderma), a potentially-life threatening autoimmune disorder with the highest mortality rate among rheumatic diseases, and has successfully completed a multi-national, phase II clinical trial. The FDA has awarded asengeprast (FT011) Orphan Drug Designation and Fast Track for the treatment of Systemic Sclerosis and the company has additional programs in play to address major indications, including chronic kidney disease, diabetic nephropathy, and other chronic fibrotic indications.

www.certatherapeutics.com



Prof Darren Kelly
CEO, Founder
Email: dkelly@certatherapeutics.com



Dr Simona Carbone
Business Development Associate
Email: scarbone@certatherapeutics.com



BIO International Convention 2025 Victorian Exhibitor Directory



Clinibase

Clinibase is a tech-driven clinical trial recruitment and site management company, ensuring studies recruit on time with zero financial risk to sponsors and CROs. Our performance-based pricing means we deliver - no excuses.

We solve clinical trials' biggest challenges: recruitment and real-time data. Our proprietary platform finds potential patients fast, while our 60-person-strong recruitment team ensures your study gets not just leads, but actual, pre-screened, engaged participants showing up at your sites.

Clinibase's recruitment approach has been proven across 50+ studies and 1,700+ enrolled participants over the past year alone. We help sites fill tough protocols, optimize operations, and provide Sponsors and CROs with real-time insights that drive trial success.

Looking for faster, risk-free recruitment with better data? Let's talk.

www.clinibase.com



Ms Pam Ramali
CEO



BIO International Convention 2025 Victorian Exhibitor Directory



Complete Phase CRO Pty Ltd

Complete Phase CRO is a leading Contract Research Organization offering full-spectrum clinical research services to the pharmaceutical and biotechnology industry. We provide expertise across all stages of clinical trials, from early-phase studies through to post-marketing, with a strong emphasis on regulatory compliance, data management, and patient recruitment.

Our approach is built on delivering customized, efficient, and cost-effective solutions designed to accelerate product development. We prioritize quality, speed, and strategic collaboration, ensuring timely, successful outcomes for our clients.

With extensive experience managing trials across multiple regions and a global presence, we are the trusted partner for companies navigating the complexities of clinical research. Our flexibility, expertise, and dedication make us the ideal choice for organizations looking for reliable support in their clinical development needs. Partner with Complete Phase CRO for a seamless, efficient approach to advancing your next clinical project.

www.completephase.com



Ms Negin Rahmani
Managing Director

Email: negin@completephase.com

Phone: +61 490 211 633

Ms Eliana Burke

Business Development Manager

Email: eliana@completephase.com



BIO International Convention 2025 Victorian Exhibitor Directory



Cooperative Trials Group for Neuro-Oncology (COGNO)

The Cooperative Trials Group for Neuro-Oncology (COGNO) is Australia's national clinical trials group dedicated to improving outcomes for people living with brain and spinal tumors through high quality, collaborative research.

We design, coordinate, and deliver world class scientifically rigorous and patient-centered clinical trials that accelerate access to promising new therapies, by bringing together top-tier clinicians, researchers and institutions across a national network.

With deep expertise in brain and spinal cancers and strong operational capability, we are the premier gateway to Australia's neuro-oncology clinical trials landscape, offering international biotech, pharma, CROs, and research consortia an established, collaborative platform for impactful research.

COGNO is seeking to partner with those that wish to expand their trial footprint, accelerate development, and contribute to a global effort to improve outcomes in one of the most challenging areas of cancer.

www.cogno.org.au




Dr Vino Pillay
Executive Officer

Email: vino.pillay@cogno.org

Phone: +61 415 176 029



BIO International Convention 2025 Victorian Exhibitor Directory



Crux Biolabs

Crux Biolabs is an Australian bioanalytical laboratory specializing in PBMC processing, pharmacodynamics (biomarker, flow cytometry – spectral and conventional – and ADA) and pharmacokinetics (large and small molecule) for clinical research.

Our expert scientists can customize and validate a wide range of biomarker and cell assays in our ISO 17025-accredited lab in Melbourne, Australia. We also offer PBMC processing in Sydney with our dedicated satellite laboratory.

We understand that each study is unique. That's why we take pride in becoming an extension of your team to deliver the best outcome for your clinical studies.

Crux Biolabs - where science leads.

www.cruxbiolabs.com



Dr Paul Della Gatta
Head of Business Development
Email: paul.dellagatta@cruxbiolabs.com
Phone: +61 404 748 865



Mr Stefan Cross
Chief Executive Officer
Email: stefan.cross@cruxbiolabs.com
Phone: +61 477 411 311



BIO International Convention 2025 Victorian Exhibitor Directory



Cyclotek

Cyclotek is a radiopharmaceutical contract development and manufacturing organisation (CDMO). Our mission is to make radiopharmaceuticals accessible in the Asia Pacific (APAC). Cyclotek offers a full CDMO service that spans the entire radiopharmaceutical value chain. We partner with local and international pharmaceutical/biotech companies to develop, manufacture and supply the highest quality, cGMP radiopharmaceutical products into the APAC market. Our CDMO services can be tailored to meet the development needs of our partners, enabling cost effective, phase appropriate clinical translation. Our radiopharmaceutical ecosystem offers the following services:

- Radiopharmaceutical development.
- Radiopharmaceutical manufacturing for pre-clinical studies.
- Radiopharmaceutical manufacturing for phase I-III clinical trials.
- Clinical research services, including clinical trial documentation development, human research ethics approval, clinical site selection, clinical trial start up, clinical trial monitoring, clinical trial data capture and storage.
- Radiopharmaceutical logistics management.
- Commercial scale radiopharmaceutical supply.
- Medical radioisotope manufacturing and supply

www.cyclotek.com



Mr Samuel Graf
Innovation and Partnerships Manager
Email: samuel.graf@cyclotek.com
Phone: +61 411 082 831



BIO International Convention 2025 Victorian Exhibitor Directory



Cynata Therapeutics Pty Ltd

Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus, using discoveries made at the University of Wisconsin-Madison (UWM).

UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson's group, which included the first successful isolation of human embryonic stem cells in 1998, and the derivation of induced pluripotent stem cells (iPSCs) from human adult cells in 2007. Professor Igor Slukvin, a co-founder of Cynata, was also a member of the team that conducted UWM's pioneering iPSC research.

Cynata's Cymerus platform stem cell technology is based upon extremely important and versatile stem cells known as mesenchymoangioblasts (MCAs). MCAs are a precursor of mesenchymal stem (or stromal) cells (MSCs) which are at the forefront of a new generation of treatments. Cynata's proprietary technology utilizes iPSCs originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product.

www.cynata.com



Dr Mathias Kroll

Chief Business Officer

Email: Mathias.Kroll@cynata.com

Phone: +61 429 844 532



BIO International Convention 2025 Victorian Exhibitor Directory



Denteric Pty Ltd

Denteric is a clinical stage biotechnology company developing a first in class immunotherapy to chronic inflammatory diseases related to *Porphyromonas gingivalis*. Our first indication is severe periodontal disease. Additional indications include Alzheimer's disease, cardiovascular disease and diabetes.

www.denteric.com



Ms Larisa Chisholm
Chief Operating Officer
Email: larisa.chisholm@denteric.com
Phone: +61 412 489 160



Dr Paul Cockle
Chief Scientific Officer
Email: paul.cockle@denteric.com
Phone: +1 760 936 763



BIO International Convention 2025 Victorian Exhibitor Directory



Dimerix

Dimerix Bioscience is a biopharmaceutical company developing innovative new therapies that target novel GPCR pharmacology in inflammatory renal diseases.

www.dimerix.com



Dr Robert Shepherd
Chief Commercialization Officer




Mr Corey Moors
Business Development Associate



BIO International Convention 2025 Victorian Exhibitor Directory

Doherty
Clinical
Trials LTD



Doherty Clinical Trials

Doherty Clinical Trials specializes in early phase, first-in-human and human challenge clinical trials. We provide a clinical trial model that is highly valued by academic, biotechnology and pharmaceutical partners as an efficient way to evaluate efficacy of novel vaccines and therapeutics.

With a purpose-built 25-bed facility, comprising specialized containment and isolation facilities, a dedicated PC2 laboratory, in-house pharmacy, and multiple outpatient rooms, we offer meticulous care and tailored participant experience, resulting in consistent positive feedback scores from participants.

Supported by a highly skilled management team, and coupled with a workforce of >60 experienced clinical trial professionals, including expertise in pharmaceuticals and pharmacology, medical research, translational medicine, biotechnology, quality, and pharmacovigilance, Doherty Clinical Trials is expertly placed to provide service excellence and support to local and global clients to accelerate the development of novel medicines and vaccines in a safe and ethical manner, whilst maintaining the utmost quality in data collection.

www.dohertyclinicaltrials.com



Dr Andrew Brockway
Chief Executive Officer

Email: abrockway@dohertyclinicaltrials.com

Phone: +61 435 995 441



BIO International Convention 2025 Victorian Exhibitor Directory



ENARESPIRATORY

ENA Respiratory

ENA Respiratory is a clinical-stage pharmaceutical company tackling respiratory viral infections by boosting the natural first line of defense against invading pathogens locally. Being virus-agnostic, ENA's antiviral host defense enhancers offer solutions to protect at-risk individuals against common and emerging respiratory viruses for which vaccines or direct-acting antivirals have limitations or do not exist.

The company has raised USD33 million in financing from Brandon Capital, The Minderoo Foundation, Flu Lab and Uniseed. It has been awarded a USD13.1M contract from the US Department of Defense and is an alumni member of BLUE KNIGHT, a BARDA-led initiative to accelerate novel potential solutions for future pandemics.

ENA is raising a USD25M Series B to undertake a Phase II community infection study to assess the efficacy of its lead asset, INNA-051, in reducing symptomatic infections caused by common respiratory viruses, including coronaviruses, seasonal influenza, rhinoviruses, RSV and human metapneumovirus.

www.enarespiratory.com



Dr Christophe Demaison
CEO



BIO International Convention 2025 Victorian Exhibitor Directory



Formulytica

Formulytica is a leading contract, development, and manufacturing organization (CDMO) supporting biotech and pharmaceutical companies in advancing early drug development programs. Established in 2015 by experienced PhD scientists, we specialize in formulation development, analytical method validation, and small-scale GMP manufacturing for clinical trial supply.

Our comprehensive Chemistry, Manufacturing, and Controls (CMC) services accelerate your journey from discovery to market without the need for in-house R&D teams. We excel in creating innovative formulations for prescription, over-the-counter (OTC), and cosmetic applications, with expertise in topical, oral and injectable drug delivery systems.

Located in Melbourne, Australia, Formulytica has earned a global reputation for quality and innovation, serving clients across Australia, the US, EU, and Asia. Our proven success has made us a trusted partner for multiple projects, offering tailored solutions to meet your unique development needs.

www.formulytica.com



Dr Richard Buchta
Director

Email: richard@formulytica.com

Phone: +61 3 9550 1483



Dr Michael Andrews Luke
Director

Email: michael@formulytica.com

Phone: +61 3 9550 1448



BIO International Convention 2025 Victorian Exhibitor Directory



GILZRx

GILZRx

GILZRx is a Monash University spinout company aiming to develop a small molecule as an alternative to glucocorticoid (GC) therapy for immune-mediated diseases. GILZRx is currently raising a syndicated seed funding round.

www.monash.edu/monash-innovation/impact/spinouts/gilzrx



A/Prof Sarah Jones
CEO and Founder

Email: sarah.a.jones@monash.edu

Phone: +61 487 592 429



BIO International Convention 2025 Victorian Exhibitor Directory



Global Pharma Solutions (GPS)

Biotech companies at early clinical stage of development need a wise, experienced hand to guide them through the maze of regulations and clinical trial design and operations, to get to open an IND and ultimately, FDA approval. GPS paves the way, so that your product can save and improve lives.

www.Globalpharmasolutions.com



Ms Margaret Jenkins

Founder and Managing Director

Email: margaret@globalpharmasolutions.com

Phone: +61 414 355 347



BIO International Convention 2025 Victorian Exhibitor Directory



Global R&D Pty Ltd

Global R&D is a R&D Tax consultancy with a global reach. We provide valuable, expert guidance on aspects of R&D Tax matters to companies and organisations across the world.

Global R&D provides R&D Tax Advisory services across the various Tech sectors, including Biotech, Life Sciences, MedTech, and Pharma. In addition to providing insightful and expert advice, trusted guidance, and focused resources to ensure compliant R&D Tax Incentive claims, Global R&D has already enabled clients to receive cash refunds that exceed their expectations.

Founder Dr Pavel Reddy comes with 16+ years of R&D Tax expertise, having worked for a Big 4 firm and a local respected R&D Tax advisory firm. With a Doctorate in Biology and a two-decade academic career in the Sciences, Pavel is well-placed to identify and understand the technology that underpins R&D Tax Incentive claims across several sectors. Pavel is an officially registered R&D Tax Practitioner with the Australian Tax Practitioners Board.

www.globalrnd.com.au



Dr Pavel Reddy

Director and R&D Tax Advisor

Email: pavel@globalrnd.com.au

Phone: +61 415 557 481



BIO International Convention 2025 Victorian Exhibitor Directory



GonGlobal

GonGlobal

GonGlobal is committed to radically improving the IVF patient experience and treatment success rates. Our team and advisory board have the expertise to execute on our mission to replace the injections of the five key IVF therapies with non-invasive delivery.

www.gonglobal.com



Ms Ellen Gonda

Co-Founder & CEO

Email: ellen@gonglobal.com

Phone: +61 400 422 682



Dr Igor Gonda

Co-Founder & CSO

Email: igor@gonglobal.com

Phone: +61 438 550 705



BIO International Convention 2025 Victorian Exhibitor Directory

GRIFFITH—HACK

Griffith Hack

Griffith Hack is one of Australia's leading providers of intellectual property services.

For over 100 years, we have partnered with a wide range of Australian and global clients to help protect and realize the value of their ideas and innovations.

From individual inventors and small businesses to Fortune 500 companies and leading educational, government and research institutions, we have an extensive track record of helping clients' of all sizes and levels of maturity extract maximum value from their IP assets.

With offices in Melbourne, Sydney, Brisbane and Perth, and a team of over 140 professionals - including over 60 patent & trade marks attorneys and intellectual property (IP) lawyers - we have the coverage and depth to ensure that our clients' most complex challenges can be met.

www.griffithhack.com



Dr Chris Vindurampulle
Principal, Patent Attorney
Email: chris.vindurampulle@griffithhack.com
Phone: +61 434 921 282



Dr Toby Thompson
Principal, Patent Attorney
Email: toby.thompson@griffithhack.com
Phone: +61 3 9243 8205



BIO International Convention 2025 Victorian Exhibitor Directory



Hudson Institute of Medical Research

Hudson Institute is a global leader in medical research. We make breakthrough discoveries that change lives. Hudson Institute's reputation as a center for research excellence draws leading scientists, clinicians and graduate students from around the world in pursuit of one mission - to collaborate to improve human health globally.

Our 477 scientists and students ask questions that push the boundaries of human knowledge to solve complex problems about human disease.

Clinical experience based on patient need informs our research enquiry, and our close ties with medical staff and industry support the translation of our discoveries into new preventative approaches, therapies and devices for patients.

Our tradition is steeped in clinical collaboration. For more than half a century Hudson Institute scientists have worked alongside clinicians in Melbourne hospitals - patient need provides the basis for our research, and our discoveries are rapidly implemented for patient benefit.

www.hudson.org.au



Mrs Carmela Monger

Business Development Manager

Email: carmela.monger@hudson.org.au

Phone: +61 439 023 808



BIO International Convention 2025 Victorian Exhibitor Directory



IDT Australia

IDT Australia is a TGA- and FDA-licensed GMP contract development and manufacturing organization (CDMO) with over 50 years of experience in pharmaceutical manufacturing. We specialize in small molecules, sterile injectables, high-potency compounds, and complex formulations, offering end-to-end solutions from API, early development to commercial production.

Companies attending BIO US 2025 should meet with IDT to explore high quality, cost-effective CDMO solutions with a trusted regulatory track record. Our expertise spans oncology, psychedelics, antibody-drug conjugates (ADCs), and advanced therapeutics, making us the ideal partner for biotech companies bringing innovative therapies to market.

With world-class GMP facilities and a flexible, client-focused approach, IDT provides tailored manufacturing solutions that help biopharma companies accelerate clinical trials and commercial success. If you're looking for a reliable, globally compliant CDMO with expertise in complex drug manufacturing, we invite you to connect with us at BIO US 2025. Let's discuss how IDT can support your next breakthrough.

www.idtaus.com.au



Mr Paul McDonald

CEO

Email: paul.mcdonald@idtaus.com.au

Phone: +61 412 000 000



Dr Carla Chinni

Business Development Manager

Email: carla.chinni@idtaus.com.au

Phone: +61 430 136 280



BIO International Convention 2025 Victorian Exhibitor Directory



Immunosis

Meeting with Immunosis offers companies a unique opportunity to collaborate with a leader in immune health innovation. Immunosis is at the forefront of developing personalized diagnostic products that leverage advanced genomics and AI-driven insights. By partnering with us, companies can gain access to cutting-edge technology and expertise that can enhance their own product pipelines and research capabilities.

Our flagship product, PrimDx, is for patients with Primary Immunodeficiency and has demonstrated success in clinical trials with 95% overall diagnostic accuracy. Collaborating with Immunosis means being part of a mission to revolutionize immune health and identifying the immune profile of patients with a wide range of conditions from autoimmune diseases to neurology.

Furthermore, Immunosis is committed to fostering strong partnerships, offering flexible collaboration models that can be tailored to meet the specific needs of our partners. Together, we can drive groundbreaking research, accelerate innovation, and bring life-changing therapies to market.

www.immunosis.com



Dr Simon Green

Chief Executive Officer

Email: simon.green@immunosis.com



BIO International Convention 2025 Victorian Exhibitor Directory



Inosi Therapeutics

Inosi Therapeutics is curing fibrotic disease with IRAP inhibitors.

Major fibrotic diseases include chronic kidney disease, idiopathic lung fibrosis HFpEF, a type of heart disease and systemic sclerosis. There is a paucity of effective treatment options available for fibrotic conditions.

Inosi's novel small molecule inhibitors have been shown to reverse age-mediated cardiac and renal fibrosis, and improve organ function in aged mice, and to reverse fibrosis in other models of renal and cardiac fibrotic disease. The target IRAP presents multimodal functionality at the nexus of key anti-fibrotic and anti-inflammatory pathways, supportive of a therapeutic opportunity against this target.

The high potency small molecule inhibitors developed by Inosi are suitable for oral delivery, and the company holds a strong IP position in the field.

www.inositherapeutics.com



Ms Filippa Shub

COO

Email: filippa@inositherapeutics.com



BIO International Convention 2025 Victorian Exhibitor Directory



INOVIQ Ltd

INOVIQ Ltd (ASX:IIQ) (INOVIQ) is a biotechnology company developing and commercializing an innovative portfolio of diagnostic and exosome-based solutions to improve the diagnosis and treatment of cancer and other diseases.

We are seeking partnerships for our proprietary exosome isolation technology including EXO-NET pan exosome capture research tool, customized isolation tools for specific exosome populations, biomarker discovery and diagnostics development.

www.inoviq.com



Dr Emma Ball
Chief Commercial Officer
Email: eball@inoviq.com
Phone: +61 412 295 111



BIO International Convention 2025 Victorian Exhibitor Directory



Kinoxis Therapeutics

Kinoxis Therapeutics Pty Ltd is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders.

Kinoxis' development candidates are novel, small molecules that were discovered through a medicinal chemistry and screening program at the University of Sydney. Kinoxis' compounds are protected by a comprehensive Intellectual Property portfolio, filed in all major jurisdictions.

The company is backed by Uniseed, Australia's longest running venture fund, and a consortium of sophisticated investors, and secured funding from the US National Institutes of Health National Institute on Drug Abuse for the development of its lead compound to mitigate opioid withdrawal symptoms. Kinoxis have an existing strategic partnership and licensing agreement with Boehringer Ingelheim for the development of first-in-class oxytocin targeting precision psychiatry treatments to improve the quality of life of people living with neuropsychiatric disorders.

www.kinoxistherapeutics.com



Mr Hugh Alsop
Chief Executive Officer

Email: hugh.alsop@kinoxistherapeutics.com

Phone: +61 439 080 353



Prof Michael Bowen
Chief Scientific Officer

Email: michael.bowen@kinoxistherapeutics.com

Phone: +61 416 093 594



BIO International Convention 2025 Victorian Exhibitor Directory



Kismet

We're making disability and healthcare services more accessible.

Health systems globally are facing similar pressures, including rising costs driven by increasing incidence of chronic diseases, an ageing population, inequitable access to services, and gaps in workforce and infrastructure. In addition, changing customer expectations are driving a need for more personalised, digital, seamless and integrated care experiences.

Solving these challenges is what we believe in. It's what gets us out of bed each morning. It pushes us to constantly reimagine how we can care for each other better. Care for you and your family. For all the things you need help with. For all the ways you want to help others. Across the entire world. In real time. At the incredible speed of now.

www.kismet.healthcare



Mr Patrick McGrath
Chief Corporate Affairs Officer



BIO International Convention 2025 Victorian Exhibitor Directory



Kynetyka Technologies

Kynetyka Technologies is developing DVTest - the easy early test for Deep Vein Thrombosis.

DVTest is a patented digital medical device that will revolutionize DVT testing by bringing the test right to the patient's bedside with a technology that a nurse or technician can easily operate with a result in just a few minutes. Kynetyka is looking for partners, investors and expert service providers as we plan for the pivotal studies, market access and product launch in the USA and globally over the next 2-3 years.

DVTest will speed up DVT management in hospitals and in the community, cut healthcare costs, support hospital-in-the home programs, and allow for enhanced care in regional and remote communities. And help pharma and biotech's to cost-effectively monitor patients for DVT in relevant clinical trials.

Let's meet at BIO 2025.

www.kynetyka.com.au



Mr Craig Newton

CEO

EMAIL: cnewton@kynetyka.com.au

PHONE: +61 434 674 256



BIO International Convention 2025 Victorian Exhibitor Directory



La Trobe University

La Trobe University is a leading research university in Australia, with a worldwide reputation for excellence and innovation. The Business Development and Commercialization (BD&C) Office from La Trobe University aims to create a culture and innovation ecosystem that supports entrepreneurial founders and researchers to achieve impact through translating research, research partnerships and increasing commercialization outcomes. The team also provides support through contract negotiation and intellectual property management and leads joint venture creation, spin-out opportunities, industry/commercialization grants and IP licensing.

The La Trobe Institute for Molecular Science (LIMS) brings together La Trobe University's leading researchers to work on some of the most critical problems facing our world. The Institute's areas of research strength include cancer, infectious disease and inflammation, cardiovascular disease; obesity, diabetes and stroke, neurology, and molecular biosensors amongst other underpinning areas such as artificial intelligence and digital health. The BD&C office works alongside LIMS' researchers to identify investable technologies in the biotech field and support entrepreneurial activities.

www.latrobe.edu.au

Ms Natalia Alvarez
Deputy Director, Business Development and
Commercialization
Email: CommercialResearch@latrobe.edu.au

Dr Darcelle Thompson
Senior Business Development Manager



BIO International Convention 2025 Victorian Exhibitor Directory



MONASH
University

MEDICINES
MANUFACTURING
INNOVATION
CENTRE

Medicines Manufacturing Innovation Centre, Monash University

The Medicines Manufacturing Innovation Centre (MMIC) at Monash University is a cutting-edge, industry-focused facility that supports the pharmaceutical and allied sectors in addressing diverse and often complex development challenges. Located across two sites within the Melbourne biotechnology precinct and Australian Synchrotron, MMIC offers advanced preclinical services and bespoke solutions for both industry and institutional clients. Our simple contract process ensures IP is retained by the client.

Our expertise spans formulation development, physicochemical characterization, complex assay development, scale-up manufacturing, and preclinical consultancy, ensuring tailored support for diverse pharmaceutical needs. Leveraging the extensive resources and capabilities of Monash University and our networks, the MMIC is committed to innovation and collaboration to support and grow the sector.

www.monash.edu/mmic



Dr Tri-Hung Nguyen
Senior Operations Manager
Email: tri-hung.nguyen@monash.edu
Phone: +61 3 9903 9299

Ms Christine Cussen
Business Development Consultant
Email: christine.cussen@monash.edu



BIO International Convention 2025 Victorian Exhibitor Directory



mexec - Executive Search & Recruitment

mexec 'connects people for success'.

mexec is an Executive Search Recruitment firm that assists companies in the biotechnology, health and innovation sectors to build their leadership teams.

We support recruitment at all levels to C- Suite and Board.

We also provide support to individuals seeking to transition to new roles.

www.mexec.com



Mrs Marilyn Jones
Managing Director

Email: marilyn@mexec.com

Phone: +61 401 003 553



BIO International Convention 2025 Victorian Exhibitor Directory



Molecular Life Science Biotech

MLS Bio. - Molecular Life Science Biotech

MLS Bio is an Australian biotechnology company pioneering the development of first-in-class small molecule therapeutics targeting tetraspanins, an underexplored class of transmembrane proteins critical to cancer metastasis and viral entry.

With two lead programs, MLS Bio is addressing urgent global health challenges in oncology and infectious diseases:

- **MLS269 (Oncology):** A first-in-class tetraspanin inhibitor targeting CD151, a validated driver of prostate cancer progression and metastasis, with potential applications in other solid tumors.
- **MLS289 (Infectious Diseases):** A broad-spectrum antiviral inhibiting CD81, blocking viral docking and entry across SARS-CoV-2 and other respiratory viruses.

As the first-mover in tetraspanin-targeted drug development, MLS Bio offers unique partnering and licensing opportunities for companies seeking novel, high-impact therapeutics with strong IP protection.

Meet with MLS Bio to explore collaboration and co-development opportunities at the forefront of oncology and antiviral innovation.

www.mlsbio.com



Ms Penelope Lane
CEO & Managing Director
Email: penelope@mlsbio.com
Phone: +61 408 016 016



Professor Albert Frauman
CMO
Email: albert@mlsbio.com
Phone: +61 416 198 042



BIO International Convention 2025 Victorian Exhibitor Directory



Molecule2Market

Established in 2012, Molecule2Market (M2M) is a boutique CRO dedicated to advancing Australia's contribution to the research and development of innovative medical treatments. With extensive experience, the M2M team provides high quality services across all phases of clinical research and a broad range of therapeutic areas across Australia and New Zealand. In addition, we are uniquely placed to support our geographically diverse clients through our US team.

M2M services cover all aspects of clinical research including:

- Local study sponsorship
- Project feasibility
- Site selection
- Study start-up (ethics/regulatory submissions, contract negotiation)
- Project management
- Monitoring
- Medical writing
- Safety reporting
- Audit/ Quality review.

M2M also offers the following services:

- Regulatory
- Data management/ Statistics
- Medical monitoring
- Support Australian R&D Tax incentive.

M2M is a proud member of the Association of International Contract Research Organizations (AICROS) - an alliance of local established CROs providing high quality clinical research services on a global scale.

www.molecule2.com



Ms Anne De Luca
Director/ Co-Founder
Email: anne@molecule2.com
Phone: +61 409 210 902



Ms Robin Hansen
Director/ Co-Founder
Email: robin@molecule2.com
Phone: +61 416 020 365



BIO International Convention 2025 Victorian Exhibitor Directory



MONASH University

Monash University

Monash University is Australia's largest university and is widely recognized as Australia's most entrepreneurial research institution, particularly in the commercialization of health technologies. With a robust ecosystem that bridges academic excellence and industry engagement, Monash stands out through its approach to innovation and enterprise integrating research, clinical care, and commercialization.

Home to the country's largest medical school, it operates at the heart of Australia's most expansive clinical trial network, with strategic integration across Monash Health, Alfred Health, Peninsula Health, Eastern Health, Cabrini Health and the Victorian Heart Hospital. This network supports a catchment of over 2.5 million patients and facilitates more than 25% of all clinical trials conducted nationally.

With a proven track record in discovery to preclinical research, leading expertise in innovative early-to-late-phase clinical trials, and real-world evidence generation, Monash is a trusted partner to many global pharmaceutical, biotech companies and venture capital firms, forming strategic collaborations to drive real-world impact. Its research ecosystem combines deep therapeutic expertise, regulatory know-how, and world-class infrastructure to accelerate drug and Medtech development pipelines, support regulatory submissions, and drive scalable, patient-focused innovation.

www.monash.edu



Dr Alison Greenway

Snr Director Enterprise and Partnerships

Email: alison.greenway@monash.edu

Phone: +61 459 401 065



BIO International Convention 2025 Victorian Exhibitor Directory



Murdoch Children's Research Institute

Murdoch Children's Research Institute (MCRI) is Australia's largest child health research organisation and a global leader in pediatric medical research.

Based at The Royal Children's Hospital in Melbourne and affiliated with the University of Melbourne, MCRI brings together over 1,800 researchers dedicated to improving the health and wellbeing of children through innovative research and clinical translation. The Institute's work spans a wide range of areas including genomics, stem cell medicine, infection and immunity, population health, and clinical sciences.

With a strong focus on collaboration, commercialization and global impact, MCRI drives scientific breakthroughs from bench to bedside, partnering with industry, government, and healthcare providers to deliver real-world health solutions for children and families worldwide.

www.mcri.edu.au



Ms Yuen Chang
BD Manager, Stem Cell Medicine
Email: yuen.chang@mcri.edu.au
Phone: +61 423 521 412



BIO International Convention 2025 Victorian Exhibitor Directory



Myrio Therapeutics

Myrio Therapeutics, a Melbourne-based biotechnology company, is at the forefront of antibody design. Founded in 2009 by Dr. Ben Kiefel and Matt Beasley, our team of 25 scientists, working in our PC2 laboratories, along with global subject matter experts, pushes the boundaries of what's possible. Myrio's pipeline includes several preclinical programs focused on T cell engagers and immune modulation, designed to activate the body's immune system in a highly targeted way.

Our innovative ReD platform is the only technology that generates cancer-specific antibodies for all the major HLA types. Moreover, Myrio has pioneered the ability to 'break restriction' generating antibodies that can target oncogenic driver peptides presented by more than one HLA type, thus significantly increasing the addressable patient population. This breakthrough enables the development of targeted therapeutics for a wider range of patients, including those who were previously difficult to treat with conventional therapies.

We are actively seeking partnerships to develop these promising therapies and establish spinouts or joint ventures for clinical development. Ready to join the fight against challenging diseases? Let's revolutionize healthcare together.

www.myriotx.com



Dr Graeme Wald
CEO



Ms Gouri Betigeri
Head of Business Development
Email: gouri.betigeri@myriotx.com
Phone: +61 468 408 807



BIO International Convention 2025 Victorian Exhibitor Directory

neuren

pharmaceuticals

Neuren Pharmaceuticals

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognizing the urgent unmet need, all programs have been granted "orphan drug" designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

DAYBUE (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.

Neuren's second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders, with positive results achieved in Phase II clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

www.neurenpharma.com



Mr Gerry Zhao
Chief Business Officer

Email: gzhao@neurenpharma.com



BIO International Convention 2025 Victorian Exhibitor Directory



Neuroscience Trials Australia

Neuroscience Trials Australia (NTA) is a globally recognized, full-service CRO specializing in CNS trials and beyond. With expertise spanning multiple therapeutic areas and direct access to The Florey's world-leading research, we offer unparalleled trial execution aligned with FDA, EMA, and TGA standards.

If you're looking for a trusted partner to accelerate your clinical development, let's connect and explore how NTA can support your next trial.

www.neurosciencetrialsaustralia.com



Dr Christina Sparbier
Associate Commercialization Manager
Email: christina.sparbier@florey.edu.au
Phone: +61 434 855 905



BIO International Convention 2025 Victorian Exhibitor Directory



Nexomics

Nexomics is an expert contract service provider offering oncology laboratory assays to support clinical trials and medical testing.

Our dedicated state-of-the-art laboratories are located at the Peter MacCallum Cancer Centre, one of the world's leading cancer research, education and treatment centers globally, and Australia's only public hospital solely dedicated to caring for people affected by cancer.

Nexomics offers a broad range of clinical tests for inclusion, safety monitoring, efficacy and exploratory biomarkers analysis using unparalleled access to clinical pathology samples. We also provide services for novel test development and technical expertise for assessment of new diagnostic instrumentation against a "gold standard".

We welcome collaborations with pharma, biotech companies and clinical research organisations to engage in routine and customized laboratory testing.

www.nexomics.org



Mr Shane Ryan
Head of Commercial
Email: shane.ryan@petermac.org
Phone: +61 433 263 789



Mr Minesh Lalla
Senior Business Development Manager
Email: minesh.lalla@petermac.org
Phone: +61 403 560 506



BIO International Convention 2025 Victorian Exhibitor Directory



Nucleus Network

Nucleus Network: Global Leading First-In-Human and Phase I Clinical Trial Experts

Accelerating Phase I trials for global biopharma companies in all therapeutic areas and modalities with rapid recruitment, multi-site capabilities and high quality data across Australia and the USA. Our class leading services enable delivery of highly valued, robust early phase clinical data including safety, tolerability, PK, PD and POC to help our sponsors meet and exceed their Phase I program goals in service of our mission advancing medicine, improving lives.

Our comprehensive Phase I clinical trial services encompass everything from First-in-Human healthy volunteer studies to Clinical Pharmacology [DDI, BE/BA, FE, TQT and Renal Impairment] and Proof-of-Concept trials for patient populations. With the largest Phase I bed capacity in Australia at our Melbourne and Brisbane sites, and a new clinic in Sydney set to expand our capabilities in 2025, we are equipped to meet diverse clinical needs. Our Minneapolis clinic in the USA enhances our reach, providing complete end-to-end Phase I clinical pharmacology study data through the entire life cycle of drug development.

www.nucleusnetwork.com



Chris Hickey
Chief Business Development Officer
Email: c.hickey@nucleusnetwork.com
Phone: +1 443 685 5800



Ms Teena Pisarev
Executive Management
Email: t.pisarev@nucleusnetwork.com



BIO International Convention 2025 Victorian Exhibitor Directory



Peter MacCallum Cancer Centre

Peter MacCallum Cancer Centre is a world leading cancer research, education and treatment center dedicated to improving the lives of people affected by cancer, located in Melbourne, Australia.

We have a range of novel oncology technologies stemming from our research activities and are seeking potential partners to progress these via licensing, collaboration or investment. Technologies include novel therapeutics for the treatment of cancer (small molecule, cell therapy and gene editing technologies), diagnostics and radiopharmaceuticals (theranostic agents).

www.petermac.org



Ms Lucy Pearce
Director Commercialization and Innovation
Email: lucy.pearce@petermac.org
Phone: +61 466 333 477



BIO International Convention 2025 Victorian Exhibitor Directory



Pharmachal Health Group

Pharmachal has IP certified for LNP NDDS to deliver clinical trialed range of products for commercialization, registration and marketing.

NOPAYNE is a 3 in 1 first in the world for burns, wounds and diabetic ulcers which coagulates blood in 40 seconds; anesthetic for 90 minutes in open wounds & accelerates wound healing creating new vessels and capillaries and rapid hair growth for plastic surgery and grafts.

Pharmachal IV Peptide drug for hemophilia and trauma is a world first alternative to plasma products.

LNP NDDS NOPAYNE 2% lidocaine Potoroid for post rectal surgery and hemeroids.

Pipeline products are in Nose to brain application using mRNA and other drugs for oncology and brain injury trauma.

www.pharmachal.com



Mr Charles Fridlender
Director/CEO
Email: charles@pharmachal.com
Phone: +61 439 914 592



Mr Andrew Mendelawitz
Director
Email: Andrew@pharmachal.com
Phone: +61 417 181 990



BIO International Convention 2025 Victorian Exhibitor Directory



PharmSky Research

PharmSky is a pharmaceutical contract research organisation with a focus on drug development based in Melbourne, Australia. Established with a vision to provide innovators across Australia and around the globe a launchpad to transform ideas and discoveries into registered, tangible products ready for market.

Our local leadership team members each hold over 25 years' experience in drug product development, complex formulation, injectables, regulatory and intellectual property space.

We aim to provide a premium, end-to-end service for domestic and international clients, offering contract services in new drug product design, complex formulation, process development, method development, validation and stability trials, clinical product supply and regulatory support.

The PharmSky team tailors solutions to meet our clients' needs and transforms discoveries into market ready products. Our services provide control over all aspects of CMC documentation, supported by a controlled quality management system ensuring data integrity for regulatory submission.

www.pharmsky.com.au



Mr Kyle Corcoran
Director, Business Development
Email: info@pharmsky.com.au
Phone: +61 407 626 170

Ms Julie Liu
CEO
Email: julie.liu@pharmsky.com.au
Phone: +61 428 865 535



BIO International Convention 2025 Victorian Exhibitor Directory



Prime Financial Group

Prime Financial Group has provided end-to-end accounting and tax services, including accessing the 43.5% R&D tax incentive for biotech and Medtech companies to obtain direct financial support of R&D activities conducted in Australia for over 20 years.

The company is a member of the Institute of Chartered Accountants in Australia, and we are listed on the Australian Stock Exchange (ASX). We deal primarily with biotech and Medtech start-ups conducting R&D in Australia. We would be happy to share our full service details while in attendance at this conference.

www.primefinancial.com.au



Ms Simone Quin
Partner
Email: simoneq@primefinancial.com.au
Phone: +61 433 152 463



Mr Brendan Brown
Partner
Email: brendanb@primefinancial.com.au
Phone: +61 3 9869 5900



BIO International Convention 2025 Victorian Exhibitor Directory



Proxima Bio

Proxima Bio is a venture-backed biotechnology company developing the next generation of medicines, cell surface degraders. Our technology provides new opportunities to target previously undruggable, disease-causing proteins, with powerful potential applications in autoimmune conditions and cancers.

We have an exciting platform technology that leverages our deep understanding of biologics and the cell's recycling machinery. Using our platform, partners can nominate high-value cell surface targets to co-develop potent new therapeutics with us. We also have the capacity to re-tool existing assets to engineer new potent degrader medicines. We are excited about the potential for our technology and are actively exploring partnership opportunities.

www.linkedin.com/company/proxima-bio/



Dr Jonathan Bernardini

CEO

Email: jon@proximabio.com.au

Phone: +61 413 812 823



BIO International Convention 2025 Victorian Exhibitor Directory



PureCDM Pty Ltd

Accelerate Innovation with PureCDM.

PureCDM streamlines complex clinical trial data management, ensuring global compliance and security.

Leveraging Australia's expedited regulatory pathways and generous R&D tax incentives, we empower biopharma and MedTech companies to transform data into actionable insights, optimize workflows, and fast-track life-saving treatments worldwide.

www.purecdm.com.au



Ms Helen Poliviou
Founder/Managing Director
Email: helen@purecdm.com.au



BIO International Convention 2025 Victorian Exhibitor Directory



Resolutum Global Pty Ltd

Resolutum Global is a clinical research organization (CRO) based in Australia that specializes in providing biometrics services for early phase and medical device clinical trials.

www.rgcro.com



Mrs Stella Burger
Director Client Engagement
Email: stella.burger@rgcro.com
Phone: +61 456 308 137



Mr Stephan Mynhardt
Director of Biostatistics
Email: Stephan.Mynhardt@rgcro.com
Phone: +61 401 255 930



BIO International Convention 2025 Victorian Exhibitor Directory



RSM Australia

Companies looking to explore opportunities to establish a presence in Australia should partner with RSM Australia, a world leader in the provision of audit, tax and consulting services.

We cater to entrepreneurial growth-focused organisations around the globe. We aim to foster and grow an innovative, globally competitive Healthcare Industry in Victoria. Our dedicated Life Sciences Services team provides fully integrated financial and business services to support global and domestic life sciences, pharmaceutical, biotech, and Medtech companies. We also offer critical support for undertaking R&D activities in Australia, including discovery and development, preclinical, clinical, and manufacturing related activities, commercialization and exit strategies.

www.rsm.global/australia/sector/life-sciences



Miss Aimee Whittingham
Partner, Audit and Assurance

Email: aimee.whittingham@rsm.com.au

Phone: +61 422 817 185



BIO International Convention 2025 Victorian Exhibitor Directory



SAPRO CRO

At SAPRO we collaborate closely with sponsors, researchers, and patient groups to drive the future of medicine and human health with an unwavering commitment to quality.

Our ultimate goal is to redefine the traditional image associated with CROs and transform the delivery of clinical trials. SAPRO aims to become the trusted Trial Pathway Partner (TPP) for niche biotech and early stage pharma, by offering invaluable and flexible assistance in their journey towards success.

Our collective and relevant industry experience includes running over 600 Phase 1-IV clinical trials. Our teams have experience working within the CRO industry, at site and within biotech and pharma companies.

Our approach ensures the prioritization of the patient journey and experience in clinical trials. Not only does this improve recruitment and retention, promote regulatory & ethical compliance, and foster trust amongst stakeholders, it ultimately advances medical research and improves patient outcomes.

www.sapro-cro.com



Mr Charles Beasley
Director, Strategic Partnerships
Email: charles.beasley@sapro-cro.com
Phone: +64 21 076 1315



Ms Rhona Macdonald
Director, Clinical Innovation & Delivery
Email: rhona.macdonald@sapro-cro.com
Phone: +64 21 346 768



BIO International Convention 2025 Victorian Exhibitor Directory



SeerPharma Pty Ltd

SeerPharma is a team of consultants that provide best-practice advice, training, software solutions from MasterControl, and contract labor resources to pharmaceutical and medical device companies in the Asia-Pacific (APAC) region.

Our clients are leading organisations, involved with, and/or conducting step(s) of manufacture of pharmaceutical and medical devices. We help address business problems associated with Quality and GxP compliance.

We have been serving our clients in the Asia-Pacific region for over 35 years from Melbourne, Sydney, and Singapore, and can assist in Europe through our affiliate in the UK.

Approach us to help you with due diligence GxP oversight activities in Victoria and the wider APAC region.

www.seerpharma.com



Mr Andrew Giles
Director

Email: andrew.giles@seerpharma.com.au



BIO International Convention 2025 Victorian Exhibitor Directory



Smartways Logistics

Smartways operates the largest and fastest-growing dedicated healthcare logistics network across Australia and New Zealand, with 35+ hubs and 350+ trained drivers ensuring daily, nationwide coverage. With a growing international network, we are well-positioned to support all medical-related logistics needs.

Specializing in critical, time-sensitive deliveries, we lead the industry in Patient on Table, Direct Drives, Next Flight, and Same-Day services. Operating 24/7, 365 days a year, we ensure seamless transport for labs, hospitals, surgeries, and clinical trials.

As a 100% carbon-neutral company, we fully fund our Sustainability Program, supporting global carbon offset projects.

Founded in Australia in 2004, Smartways has completed millions of shipments, including 1M+ in 2024 alone. With deep industry expertise, we deliver tailored, compliant, and dependable solutions. Smartways - redefining medical logistics, one shipment at a time.

www.smartwayslfl.com



Mr Ryan Kafoure
Commercial Director

Email: ryan.kafoure@smartwayslfl.com

Phone: +61 447 049 810



BIO International Convention 2025 Victorian Exhibitor Directory



Solubility

Solubility provides a specialized IP commercialization law service for creative businesses seeking personalised, responsive and expert legal support in commercializing their IP.

We are an efficient and pragmatic team of highly skilled award-winning professionals, most with undergraduate science qualifications in addition to legal qualifications, and with specialist and certified expertise and experience in IP commercialization law.

Our legal services comprise the following three elements:

- IP licensing and commercialization law - Developing legally viable commercialization strategies, and drafting, reviewing and negotiating licenses and other core commercialization contracts.
- Business and commercial law - Drafting, reviewing and negotiating operational and subscription/shareholder agreements and advising on operational issues arising.
- Inbound R&D legal support - Assisting international clients seeking to undertake high risk R&D in Australia, including drafting inter-company agreements and drafting, reviewing and negotiating operational agreements and advising on local operational issues arising.

www.solubility.com.au



Mr Jeff Bergmann

Director

Email: jeff.bergmann@solubility.com.au

Phone: +61 437 667 288



BIO International Convention 2025 Victorian Exhibitor Directory



St Vincent's Hospital Melbourne **St Vincent's Health Australia**

St Vincent's Hospital Melbourne (SVHM) is an acute tertiary university-affiliated health care service that has a long, rich research history.

They have approximately 1000 clinical research studies currently active with over 500 interventional clinical trials. Their research covers all areas of adult acute care, subacute and rehabilitation medicine and extends into aged care. They participate in clinical trials including drugs, devices, diagnostics, digital and combination therapeutics.

SVHM also offers a unique Research Valet™ Service supports all levels of clinical trials for staff and industry, providing sector-leading service that streamlines ethics submissions and provides globally competitive timelines.

www.svhm.org.au/research



A/Prof Megan Robertson
Director of Research
Email: megan.robertson@svha.org.au
Phone: +61 412 051 215



BIO International Convention 2025 Victorian Exhibitor Directory



Starpharma

Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient.

Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Starpharma is actively seeking new partnerships, collaborations, and licensing opportunities to utilize its dendrimer technology platform in various products and therapeutic areas for both therapeutic and diagnostic applications. By forming strategic alliances and licensing agreements, Starpharma aims to maximize the commercial potential of its technology across multiple sectors.

Discover the possibilities of Starpharma's cutting-edge DEP drug delivery platform through partnerships, collaboration and licensing. This innovative technology is supported by an extensive intellectual property portfolio. It has the potential to significantly enhance the therapeutic and commercial value of many drugs, including oncology chemotherapeutics, non-oncology molecules, antibody-drug conjugates (ADCs), and radiotheranostics, among others.

www.starpharma.com



Mr Tony Eglezos
VP, Business Development
Email: busdev@starpharma.com
Phone: +61 3 8532 2700



BIO International Convention 2025 Victorian Exhibitor Directory



Taikun Pharma Services

As the expert in global clinical services, Taikun Pharma provides bespoke clinical trial services solutions for our clients.

Whether it's optimizing flexibility in clinical supply timelines or assisting with regulatory guidelines and packaging design, Taikun Pharma is committed to delivering client centric solutions to support the success of clinical trials globally. Whether it's optimizing flexibility in clinical supply timelines or assisting with regulatory guidelines and packaging design, Taikun Pharma is committed to delivering client centric solutions to support the success of clinical trials globally.

Through our GDP/GMP compliant facilities located in Australia, U.S., Belgium, and China, and our partner depot network across South America and Europe, Taikun Pharma provides full range of clinical trial services. These services include:

- Specialized clinical supply management.
- GCP/GMP compliant packaging solutions.
- Label and carton design and manufacturing.
- Temperature-controlled storage.
- Clinical site distribution.
- Import & export of clinical materials.
- Returns and destruction services.
- IRT.

www.taikunpharma.com



Mr Isaac Huang
VP

Email: isaac.huang@taikunpharma.global

Phone: +61 466 891 508



BIO International Convention 2025 Victorian Exhibitor Directory



Telford Life Sciences

With over 15 years of experience across biotechnology and pharmaceutical companies, and CROs, we provide unbiased, strategic guidance to ensure the success of your Australian clinical program.

We are truly independent free from site/CRO affiliations or commercial biases giving you clarity, confidence, and control over your study.



Mr Sean Connell

Director

Email: seanaconnell@yahoo.com.au

Phone: +61 405 632 416



BIO International Convention 2025 Victorian Exhibitor Directory



Telix

Telix is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic ('theranostic') radiopharmaceuticals.

Telix's extensive pipeline for urologic oncology, neuro-oncology, musculoskeletal oncology and hematology is underpinned by a strong global supply, manufacturing and distribution network.


www.telixpharma.com



Ms Emma Armitage
Associate Director, Business Development



BIO International Convention 2025 Victorian Exhibitor Directory



The Florey
Advancing Brain Research

The Florey Institute of Neuroscience

As a world-leading medical research institute, our expertise, collaborations and world-class facilities mean that our knowledge can be accelerated into impact - finding treatments and advancing clinical practice to improve the lives of people living with brain and mental health conditions. Our research encompasses 20+ brain and mental health conditions including anxiety, dementia, motor neurone disease, epilepsy and stroke.

We investigate how the brain works, what drives behaviour, find the underlying causes of diseases, and unravel the connection between the body and the brain.

www.florey.edu.au



Dr Christina Sparbier
Associate Commercialization Manager
Email: christina.sparbier@florey.edu.au
Phone: +61 434 855 905



BIO International Convention 2025 Victorian Exhibitor Directory



The University of Melbourne

The University of Melbourne is a global leader in biomedical research, innovation, and commercialization. With strong industry partnerships and a proven track record in translating research into impactful health technologies, we offer unique opportunities for collaboration in the Medtech and digital health sectors.

Our multidisciplinary teams combine world-class expertise in clinical research, engineering, and education to co-develop next-generation solutions addressing critical healthcare challenges.

We have research projects available for partnering and investment that include novel vaccines, digital health technologies, Medtech devices, therapeutics for various indications including cancer, neurodegenerative diseases, and autoimmune conditions. We also have a new surgical simulation platform, developed in partnership with a major global technology company, available for investment or co-development.

www.unimelb.edu.au



Dr Dhiraj Hans
Senior Business Development Manager
Email: dhiraj.hans@unimelb.edu.au

Dr Caroline Bathje
Innovation & Partnerships Manager
Email: caroline.bathje@unimelb.edu.au



BIO International Convention 2025 Victorian Exhibitor Directory



Tianli Biotech

TianLi Biotech is a clinical stage biotech with a mission to develop innovative, safe, well-tolerated and effective inhaled and orally available drugs that alleviate suffering of patients with debilitating/fatal respiratory conditions, with IPF being the initial focus.

TianLi Biotech is a Melbourne-based start-up company founded in 2019 in collaboration with The University of Melbourne and Beijing No.1 Biotechnology Group Co., Ltd. The company leveraged the ground-breaking discovery that isoforms delta and epsilon of casein kinase 1 (CK1d/e) modulate fibrosis and inflammation, into drug developments for conditions in which fibrosis and inflammation are the main features. The company has a follow-on program with orally available inhibitors with systemic anti-fibrotic and anti-inflammatory activity.

www.tlbiotech.com.au



Prof Alastair Stewart

CSO

Email: gstew@unimelb.edu.au

Phone: +61 431 270 122



BIO International Convention 2025 Victorian Exhibitor Directory



TrialKey

TrialKey is the market leading AI Agent in clinical trial design, process automation, and protocol optimization with a +92% accuracy rate in endpoint completion prediction.

Built on data from 468,429 trials and 2.69 billion patients over the past 30 years, we help pharmaceutical, biotechnology, and CROs design and refine trials with data-backed recommendations, reducing failure risks and accelerating development timelines. TrialKey is able to make reliable predictions, even for rare conditions. For rare conditions, TrialKey achieves AUC 0.75 in Phase II trials and 0.775 in Phase III, showing strong predictive accuracy even in under-researched conditions. TrialKey delivers actionable insights for key trial elements, including:

- Clinical Trial Design Report - Optimize trial structure, patient selection, and endpoint definitions.
- Body of Research Report - Identify trends, gaps, and opportunities in your therapeutic area.
- Real-World Evidence Report - Validate trial designs with real-world patient data.
- Competitor Analysis & Prediction Report - Benchmark trials and forecast competitor success rates.
- Site Selection Report - Pinpoint the most effective trial sites based on historical performance.

We work with our CRO clients like Biointelect, Commercial Eyes (a ProductLife Group), Avion Medical, Alithia Life Sciences, Southern Clinical Development Consulting, Phenix Health, and NeuOrphan, delivering insights that drive better trial outcomes, improve trial success rates and streamline development.

www.trialkey.ai



Mr Damon Rasheed
Chief Technology Officer & Executive Director
Email: damon@trialkey.ai
Phone: +61 401 414 407



BIO International Convention 2025 Victorian Exhibitor Directory



Turquoise Biotechnologies

We manufacture targeted and loaded exosomes/extracellular vesicles in order to deliver effective therapeutic payloads such as immunotherapies, small molecules, and siRNA, to specific cells within patients' bodies.

Our unique and proprietary technology enables effective delivery of approved, new or experimental targeted therapeutics.

www.turquoisebio.com.au



Dr Majid Ghoddusi
Founder & CEO

Email: majid.ghoddusi@turquoise-bio.com

Phone: +61 407 285 086



BIO International Convention 2025 Victorian Exhibitor Directory



Veritus Research

Veritus Research is a groundbreaking clinical research organisation that is revolutionizing the field of Clinical Trials within the Australian biomedical community. Our mission is to challenge the traditional norms by decentralizing the conduction of studies that were previously limited to tertiary centers. At Veritus, we defy conventional thinking, pioneering a new way forward with our standalone custom-built, state-of-the-art clinical research facility.

This cutting-edge facility specializes in conducting Early Phase and First In Human (FIH) studies, therapeutic and vaccine trials, providing a clinically safe environment for participants. Our commitment to excellence drives us to deliver exceptional recruitment and the highest quality data to our Sponsors and stakeholders, leverage the latest advancements in technology within our modern and luxurious facility.

www.veritusresearch.com



Mr Salmaan Naqvi
Chief Commercial Officer
Email: salmaannaqvi@veritusresearch.com
Phone: +61 479 060 929

Ms Cheryl-Ann Hawkins
CEO
Email: cherylannhawkins@veritusresearch.com
Phone: +61 425 710 817



BIO International Convention 2025 Victorian Exhibitor Directory



VivaZome Therapeutics Pty Ltd

VivaZome Therapeutics is an Australian biotech company pioneering extracellular vesicle (EV)-based therapies for neuroinflammatory diseases and regenerative medicine.

Our proprietary EV platform enables the scalable manufacturing and bioengineering of high-purity, functional EVs, designed to deliver therapeutic payloads with enhanced precision and efficacy.

VivaZome's advanced analytics and GMP-aligned production ensure a high quality, consistent product ready for clinical translation.

We are actively seeking strategic partnerships with biopharma, investors, and research institutions to accelerate the commercialization of EV-based therapies. Whether you're looking for collaboration in EV manufacturing, licensing opportunities, or cutting-edge delivery solutions, VivaZome offers a powerful, next-generation biologic platform.

Connect with us to explore how EVs can revolutionize drug delivery and regenerative medicine driving breakthrough treatments and commercial success.

www.vivazome.com



Ms Xenia Sango
CEO and Managing Director

Email: xenia.sango@vivazome.com

Phone: +61 406 180 812



BIO International Convention 2025 Victorian Exhibitor Directory



WEHI

brighter together

WEHI

WEHI is an innovative medical research institute with a mission to master disease through discovery.

We have a strong track record in translation through commercialization and entrepreneurship. For example, Venetoclax, marketed globally by Genentech and Abbvie for certain forms of leukemia, has been developed based on landmark research discoveries made at WEHI.

We collaborate with private and public organisations to translate our discovery science and to ensure that patients benefit from our research. We are committed to strengthening our established partnerships as well as to fostering new relationships with pharmaceutical/biotech companies and investors to develop novel therapies to treat cancer, immune disorders, infectious diseases and developmental and ageing disorders.

www.wehi.edu.au



Dr Anne-Laure Puaux
Head of BD/CEO WEHI Ventures



Dr Seth Jones
Entrepreneurship Lead



BIO International Convention 2025 Victorian Exhibitor Directory

cencora

World Courier

World Courier

With over 40 years in Australia, World Courier is your "go to" Clinical and Commercial Pharma logistics company.

We have long standing working relationships with world class, locally based Universities, Institutes, Labs, Sites and Hospitals across Australia, to support all your Clinical Trial or Market Launch needs.

www.worldcourier.com



Mr Brent McPherson
Director, Business Development AU NZ
Email: bmcpherson@worldcourier.com.au
Phone: +61 426 226 094

MELBOURNE • VICTORIA • AUSTRALIA

